Facilities & Capacity

ReiThera opens Italy viral vector production plant

ReiThera has expanded its large-scale viral vector manufacturing capabilities at its Castel Romano Technopole plant through receiving operational authorization from the Italian Medicines Agency. According to the contract development manufacturing organization (CDMO), the recently opened 1,500 square meter facility located close to Rome will have production scales of up to 3,000 L and produce viral vectors for vaccines and gene therapies. “Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive…

Vetter Pharma ups storage capacity with warehouse expansion

Vetter Pharma has completed its €20 million ($19 million) warehouse expansion, which it says will help meet customer supply demands. Contract development manufacturing organization (CDMO) Vetter says that the fully automated building located in Ravensburg, Germany optimizes the firm’s logistical infrastructure by providing storage space for materials it considers having high-stock turnover rates, such as packaging components. The firm claims that construction of the warehouse, which began in April 2021, will mean that “valuable capacity” is freed up in the…

Fill-finish roundup: News from INCOG, Recipharm, WuXi Bio

INCOG BioPharma completes installation of a filling line in Indiana, Recipharm invests in Lab+ filling technology in France, and WuXi Biologics expands its fill-finish capacity and capability in China. Welcome to our fill-finish roundup. First up is contract development manufacturing organization (CDMO) INCOG, which specializes in sterile injectables. The firm has completed the installation of its OPTIMA multi-use production filling line at its Fishers, Indiana plant. “The OPTIMA multi-use line serves as our highly customized, injectable therapy ‘bottling line’ at…

Lonza to expand US and EU CGT lab space

Lonza will expand its cell and gene therapy (CGT) development laboratories in the US at its Houston, Texas facility and in Europe at its plant in Geleen, The Netherlands. Swiss contract development manufacturing organization (CDMO) Lonza says the expansion in Houston will include viral vector-based process development and analytical development laboratories. In addition to its Houston expansion, the firm claims it will more than double its European process development laboratory space in Geleen, The Netherlands. The CDMO will add 4,500…

Landmark Bio opens advanced therapy manufacturing plant in MA

Academia-industry joint venture firm Landmark Bio says the recently opened Watertown, Massachusetts facility offers a one-stop-shop for manufacturing solutions. Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva – the founders of Landmark Bio – collectively invested $75 million to support construction staff and early client services for the 44,000 square-foot Watertown facility that will carry out development, manufacturing, and testing of cell and gene therapies in the area. Other collaborating institutions include Beth Israel Deaconess Medical…

Andelyn opens CGT manufacturing plant in Ohio

CDMO Andelyn Biosciences has opened a clinical and commercial manufacturing facility in Columbus, Ohio to support cell and gene therapy (CGT) development. Contract development manufacturing organization (CDMO) Andelyn has opened a manufacturing facility in Ohio, which it has named the Andelyn Corporate Center (ACC). The firm says that the 200,000 square-foot gene therapy production plant has the capability to support any scale of gene therapy viral vector manufacturing. “We built the ACC in response to increasing customer demand for regulatory-compliant, high…

Fujifilm Diosynth breaks ground on $300m single-use plant

Fujifilm has begun construction on a facility in Texas described as the largest single-use CDMO production campus in North America. Fujifilm Diosynth Biotechnologies announced the expansion of its College Station, Texas facility December 2021, but work finally began yesterday with the contract development manufacturing organization (CDMO) holding a groundbreaking ceremony. Once operational – by 2024, according to the firm – the $300 million expansion will add 138,000 square feet to the existing 300,000 square feet campus, providing space for multiple…

In brief: Pfizer allegedly to invest €1bn in Irish manufacturing

Pfizer has refused to comment on claims made by the Irish press it is investing €1 billion ($1 billion) in its Grange Castle biomanufacturing site. The 90-acre manufacturing site in Clondalkin in Dublin was opened in 2006 following a $2 billion investment by Wyeth (which Pfizer acquired in 2009). The site has benefitted from continual investments and expansion since, including a $40 million mRNA expansion to support the firm’s COVID-19 vaccine efforts. But now Pfizer could be ready to invest…

Triumvira expands T cell manufacturing by setting up shop at AmplifyBio

Triumvira will expand its autologous T-cell manufacturing network by placing its staff and tech within AmplifyBio’s facilities in South San Francisco, California. Within the cell therapy space, an ongoing topic of debate is whether to build an inhouse manufacturing network or use a contract development and manufacturing organization (CDMO). But for Triumvira Immunologics, a third option has been exercised: a pact for Triumvira to manufacture its own cell therapy candidates within a facility in South San Francisco run by contract…

Univercells triples capacity with Nivelles plant completion

Univercells Technologies has completed a €2 million ($1.9 million) expansion of its Nivelles, Belgium site. Work began at the site in December 2020 and Univercells claims the expansion has doubled its overall footprint while tripling its manufacturing capacity at the plant. Furthermore, the firm says that the expansion has enabled it to provide customers with supply chain security “The first phase has provided a larger warehouse storage as well as the ISO 8 clean room space, greatly increasing capacity for…